7th Aug 2024 Jefferies maintains Neuren Pharma at 'buy' with a price target of A$29.75 An analyst from Jefferies maintained Neuren Pharma (ASX: NEU) at 'buy' with a price target of A$29.750 from a prior price target of A$31.400. Prior to this rating, Neuren Pharma had 6 buy ratings, 0 hold ratings, and 0 sell ratings. Neuren Pharma's stock price closed at A$17.09. They are down -12.360% in the last month and up 41.830% in the last 12 months.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)